The DOI matches its Crossref record.
Characterization of a Urinary Bufodienolide Na+,K+-ATPase Inhibitor in Patients After Acute Myocardial Infarction
Abstract
Abstract—Recent evidence suggests the existence of several endogenous Na+,K+-ATPase inhibitors in mammals. Previously, we have shown that the amphibian Na+,K+-ATPase inhibitor marinobufagenin (3,5-dihydroxy-14,15-epoxy bufodienolide) acts as a vasoconstrictor in isolated rat and human arteries. Mammalian plasma was shown to contain marinobufagenin-like immunoreactive material, which is responsive to saline volume expansion. The present study describes purification of a bufodienolide, which is similar to marinobufagenin, from the urine of patients after acute myocardial infarction with the use of thin-layer chromatography and reverse-phase high-performance liquid chromatography (HPLC). The purified substance cross-reacted with marinobufagenin antibody, demonstrated maximal UV absorbance at 300 nm characteristic of bufodienolides, and eluted from HPLC columns with the same retention time as marinobufagenin. Mass spectrometry of purified material revealed the presence of a substance indistinguishable from amphibian marinobufagenin and having molecular mass of 400 D. The present studies show that one of the human digitalis-like factors may have a bufodienolide structure and is likely to represent marinobufagenin or its isomer, and they suggest a role for this substance in the pathogenesis of myocardial ischemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Novel therapeutic applications of cardiac glycosides
Prassas, I., & Diamandis, E. P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2682 · Cited by 673
Endogenous Cardiotonic Steroids: Physiology, Pharmacology, and Novel Therapeutic Targets
Bagrov, A. Y., Shapiro, J. I., & Fedorova, O. V. (2009) · Pharmacological Reviews · doi:10.1124/pr.108.000711 · Cited by 532
Self-citationSchoner, W., & Scheiner-Bobis, G. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00098.2007 · Cited by 456
Endogenous cardiac glycosides, a new class of steroid hormones
Schoner, W. (2002) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2002.02911.x · Cited by 385
Iwamoto, T., Kita, S., Zhang, J., Blaustein, M. P., Arai, Y., Yoshida, S., Wakimoto, K., Komuro, I., & Katsuragi, T. (2004) · Nature Medicine · doi:10.1038/nm1118 · Cited by 267
Metadata
- Authors
- Bagrov, A. Y., Fedorova, O. V., Dmitrieva, R. I., Howald, W. N., Hunter, A. P., Kuznetsova, E. A., & Shpen, V. M.
- Venue
- Hypertension
- Published
- 1998-05
- Volume
- 31
- Issue
- 5
- Pages
- 1097-1103
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W1987534461
- Cited by
- 165
- References
- 0
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of a Urinary Bufodienolide Na+,K+-ATPase Inhibitor in Patients After Acute Myocardial Infarction. https://app.cochat.ai/papers/10.1161/01.hyp.31.5.1097
- The paper
- Bagrov, A. Y., Fedorova, O. V., Dmitrieva, R. I., Howald, W. N., Hunter, A. P., Kuznetsova, E. A., & Shpen, V. M. (1998). Characterization of a Urinary Bufodienolide Na+,K+-ATPase Inhibitor in Patients After Acute Myocardial Infarction. Hypertension. https://doi.org/10.1161/01.hyp.31.5.1097
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.